近日，2024美國癌癥研究協(xié)會(huì)（AACR）年會(huì)在美國圣地亞哥當(dāng)?shù)貢r(shí)間4月10日圓滿落幕，集萃藥康在本次會(huì)議上展示了7張海報(bào)，引發(fā)了與會(huì)者的熱烈討論。

集萃藥康展示的海報(bào)內(nèi)容涵蓋免疫重建小鼠模型、Enhertu耐藥腫瘤模型、治療性抗體的臨床前評估、HER2靶向藥物、IL-12臨床前藥物研發(fā)、人源化抗體領(lǐng)域小鼠模型、臨床前PD-1耐藥模型這7項(xiàng)研究成果：

01 Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

02 NeoMab?: A Novel Platform for Fully Human Therapeutic Antibody Development

03 Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

04 Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction

05 Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing

06 BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy

07 Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model

您可點(diǎn)擊下方鏈接下載集萃藥康A(chǔ)ACR 2024海報(bào)：https://en.www.pubugu.com/content/details100032_5210253.html